Democritus University of Thrace (DUTH)
Πλαστικότητα των ουδετεροφίλων και ρύθμιση της φλεγμονώδους απόκρισης
Abstract
dc:descriptionIntroduction: Neutrophils constitute integral components of innate immunity and major contributors to thromboinflammation and tissue damage. Neutrophil plasticity, i.e., the ability of the mature cells to acquire phenotypic heterogeneity and functional flexibility when exposed to different stimuli of the inflammatory microenvironment, has been recently recognized as a key aspect of their biology. The generation and release of neutrophil extracellular traps (NETs), chromatin structures decorated with active proteins, comprises a predominant expression of neutrophil plasticity. Numerous studies demonstrate the release of NETs (NETosis) as an important defense mechanism. However, recent data link dysregulation of the innate immune response, leading to marked NETosis, to the induction of inflammation and thrombosis. Severe SARS-CoV-2 infection (COVID-19) stands as a recently recognized example of a disease characterized by dysregulated immune response and increased release of NETs. It is associated with high rates of intubation, in-hospital mortality, and secondary complications, such as micro- and macro-thrombosis and pulmonary fibrosis, often reflecting the robust underlying processes of thromboinflammation and immunofibrosis. Krüppel-like factor 2 (KLF2) is a transcription factor linked with neutrophil-associated fibrosis and thromboinflammation. However, its role in COVID-19 remains elusive. Objectives: Considering the heterogeneity and complexity of the mechanisms that characterize the dysregulation of the immune response in severe COVID-19, combined rescue immunomodulatory treatment (COMBI) was applied for the first time on top of standard-of-care treatment (SOC), aiming to reduce the need for mechanical ventilation and mortality, in non-intubated patients with COVID-19-related severe respiratory failure (PaO2/FiO2 <100 mmHg). In the experimental part of this PhD thesis, the crosstalk between the neutrophil/NETs axis and human lung fibroblasts (LFs) was investigated, as well as the effect of plasma on LFs’ thrombotic and fibrotic potential, in the context of severe COVID-19. The possible correlation between the fibrotic activity of LFs and KLF2 expression in the COVID-19 environment was also explored. Concurrently, a comparative study of the clinical data from patients subjected to different immunomodulatory interventions was conducted, correlating the findings with the research results. The broader purpose of this research was the identification of potential future prognostic and therapeutic targets in immunofibrotic diseases with a similar pathogenetic background. Materials and methods: In the clinical part of the study, 4 groups of patients with severe respiratory failure (SRF), subjected to different treatment interventions, were analyzed and compared. Specifically, the effect of COMBI treatment, comprising inhaled DNase I, baricitinib, and tocilizumab, to dismantle NETs and inhibit JAK1/2 and IL-6 signaling, respectively, was studied. COMBI treatment was compared with SOC or immunomodulatory monotherapies against IL-1 (anakinra) or IL-6 (tocilizumab). In the translational-research component of the study, human lung fibroblasts (LFs) were isolated from patients undergoing diagnostic lung biopsy. In vitro stimulations of LFs were conducted using either plasma, obtained from treatment-naïve patients with severe COVID-19, or NET structures, isolated after in vitro incubation of healthy neutrophils with patients’ plasma (COV NETs). RT-qPCR, in-cell ELISA (Cytoblot), immunofluorescence microscopy, collagen measurement and functional wound healing assays were performed to evaluate the effect of COVID-19 environment (plasma or NETs) on LFs. In vitro inhibition studies were conducted, using the agents of COMBI protocol (DNase I, baricitinib, tocilizumab), to investigate the role of NETs, JAK1/2 and IL-6 signaling, respectively. Results: At the clinical level, COMBI treatment was associated with lower in-hospital mortality, reduced intubation rate, shorter duration of hospitalization, and prolonged overall survival, compared to other therapeutic interventions. At the experimental level, in vitro stimulation of LFs with COVID-19 environment induced the tissue factor (TF)/thrombin pathway, while pre-incubation with COMBI agents significantly inhibited this effect. Furthermore, upon incubation with COVID-19 plasma or COV NETs, LFs acquired a pre-fibrotic phenotype, characterized by increased expression of CCN2 (Cellular Communication Network Factor 2), a growth factor consistently associated with fibrotic remodeling, and increased collagen production. This effect was correlated with the down-regulation of KLF2 in LFs. However, pre-incubation of LFs with the agents of the COMBI protocol restored the reduced expression of KLF2, while mitigating their fibrotic activity. Plasma isolated from COMBI-treated patients at day 7 was characterized by a significantly reduced ability to induce the fibrotic potential of LFs (lower CCN2 expression and simultaneous restoration of the reduced expression of KLF2), compared to the plasma of SOC-treated patients. Conclusions: Collectively, COMBI rescue treatment was associated with improved clinical outcomes, compared to SOC therapy or immunomodulatory monotherapies. Severe COVID-19 environment induces the thrombotic and fibrotic potential of LFs through different pathways, including the neutrophil/NETs axis, JAK1/2 signaling, and IL-6. The dismantling of NETs by DNase I, and the subsequent inactivation of the mediators they contain, highlight, on one hand, the central role of NETosis, a process of neutrophil plasticity expression, in the thromboinflammatory and immunofibrotic process in COVID-19 and, on the other hand, the structural integrity of NETs as a prerequisite for maintaining their functionality. The in vitro results emerging from inhibition of the TF/thrombin axis and the fibrotic pathway in LFs are consistent with the above clinical observations, providing a plausible mechanistic explanation. Furthermore, the negative correlation between KLF2 expression and the fibrotic activity of LFs, suggests KLF2 as a significant regulator of the fibrotic process in severe COVID-19. Overall, the findings of this study hold potential for future applications in other acute or chronic inflammatory immunofibrotic conditions pathogenetically related to COVID-19.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Antoniadou, Christina
- Αντωνιάδου, Χριστίνα
Subjects
dc:subject × 25- Ουδετερόφιλα
- Εξωκυττάρια ουδετεροφιλικά δίκτυα χρωματίνης
- Θρομβοφλεγμονή
- Ανοσοΐνωση
- COVID-19
- Krüppel-like factor 2 (KLF2)
- Δεοξυριβονουκλεάση I (DNase I)
- JAK1/2
- Ιντερλευκίνη 6 (IL-6)
- Neutrophils
- Neutrophil extracellular traps (NETs)
- Thromboinflammation
- Immunofibrosis
- Deoxyribonuclease I (DNase Ι)
- Interleukin 6 (IL-6)
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ανοσολογία
- Κλινική Ιατρική
- Κλινική ιατρική, γενικά
- Basic Medicine
- Medical and Health Sciences
- Immunology
- Clinical Medicine
- Clinical medicine, general
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55499